Enhanced Fractionated Radiotherapy and Chemotherapy with Oxygen Therapeutic and Radiosensitizers

This inventive concept combines oxygen therapeutics with radiosensitizers and hypoxia-activated prodrugs to enhance the efficacy of fractionated radiotherapy and chemotherapy for treating glioblastoma.

The original patent disclosed the use of oxygen therapeutics in combination with repeated administrations of chemotherapy medications and/or radiation therapy. However, the patent did not address the limitations of radiosensitizers and hypoxia-activated prodrugs in enhancing the treatment outcome. This inventive concept solves the problem by introducing simultaneous administration of radiosensitizers and hypoxia-activated prodrugs with oxygen therapeutics, thereby increasing the efficacy of the treatment.

The inventive concept involves administering a water emulsion of perfluoropentane and a radiosensitizer simultaneously to a subject suffering from glioblastoma. The radiosensitizer enhances the sensitivity of tumor cells to radiation therapy, while the oxygen therapeutic increases oxygenation of the tumor cells. Additionally, the inventive concept includes administering a hypoxia-activated prodrug that is activated by the oxygenation of the tumor cells, further enhancing the treatment outcome. The system for treating glioblastoma comprises a multi-fraction radiotherapy or chemotherapy apparatus, a perfluoropentane emulsion administration device, and a radiosensitizer administration device.

The simultaneous administration of radiosensitizers and hypoxia-activated prodrugs with oxygen therapeutics is a novel and non-obvious improvement over the original patent, providing a significant enhancement in the treatment outcome.

Alternative embodiments of the inventive concept include administering the radiosensitizer and hypoxia-activated prodrug sequentially, or using different types of oxygen therapeutics and radiosensitizers. Variations of the system include using different administration devices and apparatuses.

The inventive concept has significant commercial potential in the treatment of glioblastoma and other solid tumors, with a target market in the pharmaceutical and medical device industries.